NCT04349280终止1 期
A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer With Disease Progression or Recurrence Following Treatment With a Platinum Agent
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Confirmed Overall Response Rate (ORR) Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
研究概览
简要总结
The purpose of this study is to evaluate bintrafusp alfa in participants with metastatic or locally advanced urothelial cancer. This trial provides the first evaluation of bintrafusp alfa in participants with urothelial cancer that has progressed following platinum therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
盲法说明
This is an open label study.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants can give signed informed consent/assent.
- •Participants with histologically confirmed locally advanced or metastatic or locally advanced/unresectable urothelial carcinoma (including renal, pelvis, ureter, urinary bladder, urethra).
- •Able to provide, a tumor tissue sample collected during screening and prior to administration of bintrafusp alfa.
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-
- •Participants with adequate organ system functions.
- •Life expectancy of at least 12 weeks.
- •A female is eligible if she is not pregnant or breastfeeding.
排除标准
- •Active brain and/or leptomeningeal disease that is symptomatic or requires therapeutic intervention. Participants with asymptomatic central nervous system (CNS) metastases who are clinically stable as demonstrated by serial brain images and have no requirement for corticosteroids for at least 14 days prior to enrollment are eligible.
- •History of malignancy other than urothelial cancer within the last 3 years except for localized tumors that have been treated with curative intent or have not required therapy in the past 2 years. (e.g., resected non-melanoma skin cancer).
- •No more than 2 lines of systemic therapy for the treatment of metastastic disease. If the most recent therapy was not a platinum-based regimen, the participant must have progressed on or after that therapy.
- •Cirrhosis or current unstable liver or biliary disease per investigator assessment.
- •Current pneumonitis or history of non-infectious pneumonitis that required systemic immunosuppressive treatment.
- •Active autoimmune disease that required systemic immunosuppressive treatment within the past 2 years.
- •Received prior allogeneic/autologous bone marrow or solid organ transplant.
- •Receiving systemic corticosteroids (>10 milligrams [mg] daily oral prednisone or equivalent) or other immunosuppressive agent within 7 days prior to study treatment. Inhaled or topical steroids are permitted.
- •Known severe hypersensitivity reactions to monoclonal antibodies or any ingredient used in the study treatment formulation (Grade >=3 National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0).
- •Active infection requiring systemic therapy.
- •Received any live vaccine within 30 days prior first dose of intervention.
- •Known history of positive test for human immunodeficiency virus (HIV) with the exception of participants with cluster of differentiation 4 (CD4) + T-cell (CD4+) counts >=350 cells per microliter (cells /uL) and no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections.
- •Active hepatitis B virus (HBV) (HBV surface antigen-positive).
- •Active hepatitis C virus (HCV) infection, or positive HCV antibody, with the exception of participants that
- •Have HCV viral load below the limits of quantitation and
- •Completed curative antiviral therapy or are receiving and compliant with antiviral therapy.
- •History or evidence of cardiac abnormalities within the 6 months prior to first dose of intervention.
- •Participants with history of bleeding diathesis or recent major bleeding events considered by the Investigator as high risk for investigational drug treatment are also excluded.
- •Any other serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the participant to receive protocol therapy, or interfere with the interpretation of study results.
- •Received prior systemic anti-cancer therapy within 2 weeks prior to study treatment.
- •Received prior therapy with an anti-programmed death 1 (PD-1), anti-programmed death Ligand 1 (anti-PD-L1), anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
- •Received prior therapy targeting transforming growth factor (TGF) beta - (e.g., Galunistertib).
- •Received radiation therapy (or other non-systemic disease therapy) within 2 weeks prior to study treatment.
- •Undergone major surgery within 4 weeks prior to administration of study treatment.
研究组 & 干预措施
Participants receiving bintrafusp alfa
Experimental
Participants will receive bintrafusp alfa.
干预措施: Bintrafusp alfa (Drug)
结局指标
主要结局
Confirmed Overall Response Rate (ORR) Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
时间窗: Up to approximately 22 months
Confirmed overall response rate (ORR) defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) via investigator assessment per RECIST (Response Evaluation Criteria In Solid Tumors Criteria) v1.1 relative to the total number of participants in the analysis population. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm).
次要结局
- Number of Participants With Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs)(Up to approximately 22 months)
- Number of Participants With Worst Grade Treatment Emergent AEs(Up to approximately 22 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical CancerUterine Cervical NeoplasmsNCT04246489EMD Serono Research & Development Institute, Inc.146
终止
2 期
Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of Head and NeckNCT04428047UNICANCER7
终止
2 期
Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung CancerResectable Lung Non-Small Cell CarcinomaStage I Lung Cancer AJCC v8Stage IA1 Lung Cancer AJCC v8Stage IA2 Lung Cancer AJCC v8Stage IA3 Lung Cancer AJCC v8Stage IB Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8Stage IIA Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8NCT04560686M.D. Anderson Cancer Center2
进行中（未招募）
1 期
A phase II trial assessing Bintrafusp alfa, a bifunctional fusion protein targeting TGF-ß and PD-L1, in a pre-operative setting for resectable and untreated head and neck squamous cell carcinomaEUCTR2019-004052-11-FRICANCER59
终止
2 期
Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung CancerStage IVB Lung Cancer AJCC v8Unresectable Lung Non-Squamous Non-Small Cell CarcinomaLocally Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8NCT04971187M.D. Anderson Cancer Center3